Paul W H I Parren Selected Research

Paul W H I Parren Research Topics

Disease

53	Neoplasms (Cancer) 11/2023 - 10/2004
15	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 09/2004
13	Multiple Myeloma 11/2023 - 02/2011
6	Infections 01/2022 - 05/2002
6	Lymphoma (Lymphomas) 11/2016 - 09/2004
5	Autoimmune Diseases (Autoimmune Disease) 12/2023 - 01/2008
4	Hematologic Neoplasms (Hematological Malignancy) 11/2016 - 02/2011
3	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2011
3	Myasthenia Gravis 01/2021 - 01/2008
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2015 - 09/2004
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 03/2012
2	Lung Neoplasms (Lung Cancer) 01/2016 - 03/2008
2	Exanthema (Rash) 01/2016 - 01/2012
2	Inflammation (Inflammations) 01/2012 - 07/2008
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2011 - 10/2010
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2023
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/2023
1	Muscle Weakness 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2018
1	Leukemia 03/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2016
1	Plasmacytoma 03/2016
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016
1	Confusion (Bewilderment) 01/2016
1	Disease Progression 02/2014
1	Carcinogenesis 09/2011

Drug/Important Bio-Agent (IBA)

22	Monoclonal AntibodiesIBA 01/2022 - 09/2004
21	AntibodiesIBA 01/2021 - 01/2008
20	Complement System Proteins (Complement)IBA 12/2023 - 09/2004
14	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2004
10	Immunoglobulin G (IgG)IBA 01/2021 - 05/2002
10	daratumumabIBA 03/2017 - 02/2011
8	EpitopesIBA 12/2023 - 07/2006
8	Immunoconjugates (Immunoconjugate)IBA 01/2018 - 02/2014
7	Rituximab (Mabthera)FDA Link 02/2016 - 09/2004
5	CytokinesIBA 01/2023 - 11/2003
4	ofatumumab FDA Link 02/2016 - 07/2008
4	zalutumumabIBA 01/2012 - 10/2008
3	AutoantibodiesIBA 12/2023 - 01/2017
3	Fc Receptors (Fc Receptor)IBA 12/2023 - 04/2010
3	Phosphotransferases (Kinase)IBA 01/2021 - 03/2008
3	Proteins (Proteins, Gene)FDA Link 11/2016 - 05/2015
3	Lenalidomide (CC 5013)FDA Link 06/2015 - 02/2011
3	LigandsIBA 03/2014 - 08/2006
2	Single-Domain AntibodiesIBA 01/2023 - 01/2021
2	amivantamab-vmjwIBA 01/2021 - 01/2016
2	Cholinergic ReceptorsIBA 01/2017 - 01/2008
2	Tyrosine Kinase InhibitorsIBA 01/2016 - 03/2008
2	Thromboplastin (Tissue Factor)IBA 05/2015 - 02/2014
2	Interleukin-8 (Interleukin 8)IBA 01/2012 - 07/2008
2	VaccinesIBA 01/2011 - 01/2003
2	zanolimumabIBA 10/2008 - 10/2007
2	Immunoglobulins (Immunoglobulin)IBA 01/2006 - 11/2003
2	Interleukin-15 (Interleukin 15)IBA 09/2005 - 11/2003
1	Immune Checkpoint InhibitorsIBA 11/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	Mevalonic Acid (Mevalonate)IBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	muskIBA 01/2021
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 10/2020
1	TetraspaninsIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018
1	Therapeutic UsesIBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018
1	CarbohydratesIBA 11/2016
1	DNA (Deoxyribonucleic Acid)IBA 11/2016
1	Cancer VaccinesIBA 11/2016
1	AntigensIBA 11/2016
1	Lysosomal Membrane ProteinsIBA 11/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 11/2016
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 11/2016
1	Chimeric Antigen ReceptorsIBA 01/2016
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2016
1	Antigen Receptors (Antigen Receptor)IBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 01/2016
1	Bortezomib (Velcade)FDA Link 06/2015
1	monomethyl auristatin EIBA 05/2015
1	Bispecific AntibodiesIBA 01/2015
1	ibrutinibIBA 01/2015
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2015
1	idelalisibIBA 01/2015
1	AutoantigensIBA 03/2014
1	Ado-Trastuzumab EmtansineIBA 03/2014
1	Antineoplastic Agents (Antineoplastics)IBA 02/2014
1	auristatinIBA 02/2014
1	Factor VIIa (Activated Factor VII)IBA 02/2014
1	Immunoglobulin A (IgA)IBA 08/2013
1	LuciferasesIBA 07/2012
1	CCAAT-Enhancer-Binding ProteinsIBA 03/2012
1	Complement Receptors (Complement Receptor)IBA 12/2011
1	Freund's AdjuvantIBA 11/2011
1	Myelin-Oligodendrocyte GlycoproteinIBA 11/2011
1	epidermal growth factor receptor VIIIIBA 10/2011
1	Glycoproteins (Glycoprotein)IBA 02/2011
1	Panitumumab (Vectibix)FDA Link 01/2010

Therapy/Procedure

24	Therapeutics 01/2022 - 10/2004
10	Immunotherapy 01/2022 - 04/2010
2	Drug Therapy (Chemotherapy) 06/2015 - 04/2012
1	Subcutaneous Injections 01/2012